Nuclear maspin expression as a predictive marker for fluorouracil treatment response in colon cancer
- 22 March 2015
- journal article
- research article
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 54 (4) , 470-479
Abstract
Background. Maspin is a member of the serpin family of protease inhibitors whose function in colorectal cancer is not fully understood. The objective of this study was to determine whether level of maspin expression could have prognostic or predictive value in colorectal cancer. Material and methods. Maspin expression was assessed using immunohistochemistry on tissue microarrays obtained from 380 patients with stage II and III colorectal cancer randomized to adjuvant chemotherapy with fluorouracil and levamisole (5-FU/Lev) or to surgery only (control), with scores (0–300) based on presence (0–100) and intensity (0–3) of maspin expression. Associations with disease-free survival (DFS), cancer-specific survival (CSS) and prognostic factors were determined. Results. Maspin expression was predominantly nuclear and present in tumor tissue in 99% of the cases. No associations with clinicopathological factors were identified. In colon cancer patients receiving adjuvant chemotherapy, maspin expression level was significantly associated with CSS [HR 1.43 per 50 points increase in maspin score (p = 0.021)] in multivariate analyses, and a significant interaction between treatment status and maspin expression (p = 0.045) was found. Kaplan-Meier plots from colon cancer patients showed a significant treatment benefit in patients with low maspin expression, but not for individuals with medium/high expression. Level of maspin expression was not significantly related to clinical outcome in rectal cancer or in any of the control groups. Conclusions. In patients with colon cancer a low nuclear maspin expression was an independent predictor of benefit from adjuvant chemotherapy with 5-FU/Lev. A prognostic value of maspin expression was not found in this material.Keywords
This publication has 30 references indexed in Scilit:
- Role of maspin in cancerClinical and Translational Medicine, 2013
- Maspin: molecular mechanisms and therapeutic implicationsCancer and Metastasis Reviews, 2012
- Maspin is a deoxycholate-inducible, anti-apoptotic stress-response protein differentially expressed during colon carcinogenesisClinical and Experimental Gastroenterology, 2011
- Oxaliplatin As Adjuvant Therapy for Colon Cancer: Updated Results of NSABP C-07 Trial, Including Survival and Subset AnalysesJournal of Clinical Oncology, 2011
- Clinicopathological correlates and prognostic significance of maspin expression in 450 patients after potentially curative resection of node‐positive colonic cancerHistopathology, 2010
- Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosisBritish Journal of Cancer, 2009
- Nuclear and cytoplasmic Maspin expression in primary non-small cell lung cancerJournal of Clinical Pathology, 2006
- Expression of Maspin in Non-Muscle Invasive Bladder Carcinoma: Correlation with Tumor Angiogenesis and PrognosisEuropean Urology, 2004
- Is there a standard adjuvant treatment for colon cancer?European Journal of Cancer, 1998
- Levamisole and Fluorouracil for Adjuvant Therapy of Resected Colon CarcinomaNew England Journal of Medicine, 1990